Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Apr 23, 2024 11:23am
59 Views
Post# 36003318

RE:RE:RE:EU Legislative proposals aims to expedite new medicines

RE:RE:RE:EU Legislative proposals aims to expedite new medicinesLast week's international adoption of the expedited approval process of biologics drugs that address orphan diseases and those diseases (i.e. cancers) with "unmet treatment needs" , while collectively providing these biological drugs with 13 years of marketing exclusivity in the US, EU and the UK, Roche's acquisition of marketing approval in Canada for TecentriqSC could now serve as a significant catalyst for the acquisition of ONCY and then towards the international approval of ONCY's pelareorep in combination with immune checkpoint inhibitors, PLUS pelareorep's combination with bispecifcs, ADCs, CAR-T therapy, and small molecules like PARP and CDK 4/6 inhibitors. for example.

https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=36003279
<< Previous
Bullboard Posts
Next >>